

MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.
You can purchase shares of MAIA Biotechnology (AMEX:MAIA) through any online brokerage.
Other companies in MAIA Biotechnology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
There is no analysis for MAIA Biotechnology to provide a consensus price target.
The stock price for MAIA Biotechnology (AMEX: MAIA) is $ last updated .
There are no upcoming dividends for MAIA Biotechnology.
MAIA Biotechnology does not have any upcoming earnings scheduled.
There is no upcoming split for MAIA Biotechnology.
MAIA Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents...